Stratos Develops Biochip as Alternative To ELISA for Biomarker Validation | GenomeWeb
Life science startup Stratos Biosystems has developed a technology that can validate proteins and biomarkers, and that it says is both quicker and less expensive than the standard ELISA method.
 
The enzyme-linked immunosorbent assay procees can take up to two years and cost up to $2 million. Stratos’ approach, which it calls immunoaffinity mass spectrometry, takes about half the time to develop at a fraction of that cost, according to company co-founders, Allan Stephan and Mark Stolowitz.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.